Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders, according to the presenters' agreement to release them.
Login and Watch now!
ESMO Virtual Plenary: March 2023
- Start date
- 27 Mar 2023
- End date
- 28 Mar 2023
- Location
- Virtual Meeting
Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Monday, 27 March 2023 |
Tuesday, 28 March 2023 |
|---|---|
18:30-19:30 CEST |
13:00-14:10 CEST |
Programme
Welcome and introduction, Scientific background and context Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) Critical analysis and perspectives AACR Expert Commentary Discussion and Q&A (i) |
Programme
Virtual Plenary Expert Insights: Webcast of 27 March presentations, Discussion and Q&A (ii) Chair: David SP Tan, NUHS - National University Health System, Singapore Mansoor Mirza, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark Ilaria Colombo, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland Kenichi Harano, National Cancer Center Hospital East, Kashiwa, Japan Byoung-Gie Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Clare Scott, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia |
